American Samoa

American Samoa

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
5.38 (4.45 - 6.28) 2019 Modelled IHME
5.45 (4.51 - 6.44) 2018 Modelled IHME
5.5 (4.46 - 6.67) 2017 Modelled IHME
5.57 (4.56 - 6.56) 2016 Modelled IHME
5.61 (4.55 - 6.64) 2015 Modelled IHME
5.61 (4.60 - 6.62) 2014 Modelled IHME
5.6 (4.58 - 6.60) 2013 Modelled IHME
5.59 (4.56 - 6.57) 2012 Modelled IHME
5.58 (4.56 - 6.54) 2011 Modelled IHME
5.57 (4.48 - 6.57) 2010 Modelled IHME
5.59 (4.49 - 6.60) 2009 Modelled IHME
5.62 (4.49 - 6.65) 2008 Modelled IHME
5.65 (4.48 - 6.76) 2007 Modelled IHME
5.68 (4.50 - 6.82) 2006 Modelled IHME
5.69 (4.48 - 6.86) 2005 Modelled IHME
5.67 (4.51 - 6.80) 2004 Modelled IHME
5.62 (4.53 - 6.69) 2003 Modelled IHME
5.55 (4.54 - 6.57) 2002 Modelled IHME
5.5 (4.51 - 6.50) 2001 Modelled IHME
5.48 (4.49 - 6.49) 2000 Modelled IHME
5.51 (4.53 - 6.53) 1999 Modelled IHME
5.58 (4.56 - 6.71) 1998 Modelled IHME
5.66 (4.59 - 6.91) 1997 Modelled IHME
5.73 (4.58 - 7.08) 1996 Modelled IHME
5.76 (4.57 - 7.18) 1995 Modelled IHME
5.76 (4.56 - 7.16) 1994 Modelled IHME
5.75 (4.57 - 7.12) 1993 Modelled IHME
5.73 (4.56 - 7.08) 1992 Modelled IHME
5.7 (4.56 - 6.98) 1991 Modelled IHME
5.65 (4.53 - 6.86) 1990 Modelled IHME
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
2.57 (1.80 - 3.36) 2019 Modelled IHME
2.55 (1.75 - 3.31) 2018 Modelled IHME
2.55 (1.72 - 3.40) 2017 Modelled IHME
2.59 (1.77 - 3.48) 2016 Modelled IHME
2.63 (1.81 - 3.67) 2015 Modelled IHME
2.62 (1.81 - 3.62) 2014 Modelled IHME
2.59 (1.79 - 3.53) 2013 Modelled IHME
2.56 (1.75 - 3.48) 2012 Modelled IHME
2.53 (1.73 - 3.45) 2011 Modelled IHME
2.52 (1.71 - 3.47) 2010 Modelled IHME
2.54 (1.74 - 3.48) 2009 Modelled IHME
2.58 (1.79 - 3.50) 2008 Modelled IHME
2.64 (1.83 - 3.56) 2007 Modelled IHME
2.69 (1.88 - 3.61) 2006 Modelled IHME
2.71 (1.88 - 3.65) 2005 Modelled IHME
2.71 (1.87 - 3.63) 2004 Modelled IHME
2.7 (1.86 - 3.60) 2003 Modelled IHME
2.69 (1.84 - 3.59) 2002 Modelled IHME
2.68 (1.82 - 3.61) 2001 Modelled IHME
2.68 (1.81 - 3.65) 2000 Modelled IHME
2.69 (1.82 - 3.64) 1999 Modelled IHME
2.72 (1.82 - 3.63) 1998 Modelled IHME
2.75 (1.80 - 3.68) 1997 Modelled IHME
2.78 (1.79 - 3.75) 1996 Modelled IHME
2.79 (1.76 - 3.81) 1995 Modelled IHME
2.8 (1.80 - 3.79) 1994 Modelled IHME
2.8 (1.81 - 3.82) 1993 Modelled IHME
2.8 (1.83 - 3.86) 1992 Modelled IHME
2.8 (1.86 - 3.89) 1991 Modelled IHME
2.8 (1.88 - 3.91) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
54 (45 - 63) 2019 Modelled IHME
54 (45 - 63) 2018 Modelled IHME
54 (46 - 63) 2017 Modelled IHME
54 (46 - 63) 2016 Modelled IHME
54 (46 - 63) 2015 Modelled IHME
54 (46 - 63) 2014 Modelled IHME
54 (45 - 63) 2013 Modelled IHME
54 (46 - 62) 2012 Modelled IHME
54 (46 - 63) 2011 Modelled IHME
54 (45 - 63) 2010 Modelled IHME
54 (45 - 62) 2009 Modelled IHME
53 (45 - 62) 2008 Modelled IHME
53 (45 - 62) 2007 Modelled IHME
53 (45 - 62) 2006 Modelled IHME
53 (45 - 62) 2005 Modelled IHME
53 (44 - 62) 2004 Modelled IHME
53 (44 - 62) 2003 Modelled IHME
53 (45 - 62) 2002 Modelled IHME
53 (45 - 62) 2001 Modelled IHME
54 (46 - 63) 2000 Modelled IHME
54 (46 - 63) 1999 Modelled IHME
54 (46 - 63) 1998 Modelled IHME
55 (46 - 64) 1997 Modelled IHME
55 (46 - 63) 1996 Modelled IHME
55 (46 - 64) 1995 Modelled IHME
55 (47 - 64) 1994 Modelled IHME
55 (47 - 64) 1993 Modelled IHME
55 (47 - 65) 1992 Modelled IHME
55 (47 - 64) 1991 Modelled IHME
55 (47 - 65) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.29 (0.23 - 0.36) 2019 Modelled IHME
0.29 (0.23 - 0.36) 2018 Modelled IHME
0.29 (0.23 - 0.35) 2017 Modelled IHME
0.28 (0.23 - 0.35) 2016 Modelled IHME
0.28 (0.23 - 0.35) 2015 Modelled IHME
0.28 (0.23 - 0.35) 2014 Modelled IHME
0.28 (0.23 - 0.35) 2013 Modelled IHME
0.29 (0.23 - 0.35) 2012 Modelled IHME
0.29 (0.23 - 0.35) 2011 Modelled IHME
0.29 (0.23 - 0.35) 2010 Modelled IHME
0.28 (0.22 - 0.34) 2009 Modelled IHME
0.25 (0.20 - 0.31) 2008 Modelled IHME
0.22 (0.18 - 0.27) 2007 Modelled IHME
0.19 (0.16 - 0.23) 2006 Modelled IHME
0.18 (0.15 - 0.22) 2005 Modelled IHME
0.18 (0.15 - 0.22) 2004 Modelled IHME
0.18 (0.15 - 0.22) 2003 Modelled IHME
0.18 (0.15 - 0.22) 2002 Modelled IHME
0.18 (0.15 - 0.22) 2001 Modelled IHME
0.18 (0.15 - 0.22) 2000 Modelled IHME
0.19 (0.15 - 0.23) 1999 Modelled IHME
0.21 (0.17 - 0.25) 1998 Modelled IHME
0.23 (0.18 - 0.29) 1997 Modelled IHME
0.26 (0.21 - 0.32) 1996 Modelled IHME
0.28 (0.22 - 0.34) 1995 Modelled IHME
0.3 (0.24 - 0.36) 1994 Modelled IHME
0.31 (0.25 - 0.37) 1993 Modelled IHME
0.33 (0.27 - 0.39) 1992 Modelled IHME
0.34 (0.28 - 0.40) 1991 Modelled IHME
0.35 (0.29 - 0.42) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
20 (14 - 27) 2019 Modelled IHME
20 (13 - 26) 2018 Modelled IHME
19 (13 - 26) 2017 Modelled IHME
19 (13 - 26) 2016 Modelled IHME
19 (13 - 26) 2015 Modelled IHME
20 (14 - 26) 2014 Modelled IHME
20 (14 - 26) 2013 Modelled IHME
20 (14 - 27) 2012 Modelled IHME
20 (13 - 26) 2011 Modelled IHME
20 (14 - 26) 2010 Modelled IHME
20 (14 - 26) 2009 Modelled IHME
20 (14 - 26) 2008 Modelled IHME
20 (14 - 26) 2007 Modelled IHME
20 (14 - 26) 2006 Modelled IHME
20 (13 - 26) 2005 Modelled IHME
20 (13 - 26) 2004 Modelled IHME
20 (14 - 26) 2003 Modelled IHME
20 (13 - 26) 2002 Modelled IHME
20 (13 - 26) 2001 Modelled IHME
19 (13 - 26) 2000 Modelled IHME
19 (13 - 26) 1999 Modelled IHME
19 (13 - 26) 1998 Modelled IHME
19 (13 - 26) 1997 Modelled IHME
19 (13 - 26) 1996 Modelled IHME
19 (13 - 26) 1995 Modelled IHME
19 (13 - 26) 1994 Modelled IHME
19 (13 - 26) 1993 Modelled IHME
19 (13 - 26) 1992 Modelled IHME
19 (13 - 26) 1991 Modelled IHME
20 (13 - 26) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
5.38 (%)
2019
(4.45 - 6.28(%))
IHME
HCV (RNA/cAg+)
0.29 (%)
2019
(0.23 - 0.36(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
5
2019
(4 - 6)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
2
2019
(2 - 3)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
2.57 (%)
2019, latest modelled
(1.80 - 3.36(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines